Advocating for policies that grow our state’s bioscience industry.

In this fast-moving industry, BioCT keeps policy makers and influencers abreast of the latest developments and changing needs of the bioscience community.

Our mission is to provide education and advocacy for Connecticut’s bioscience and life science communities at the policy level and ensure synergy of action and alignment of state and federal initiatives that have a significant impact on our members.

Government Affairs Committee

The Government Affairs Committee is comprised of BioCT board members, industry executives and business advisors including the government relations firm of Rome, Smith & Lutz, which has deep expertise in matters impacting our industry.

Dawn Hocevar
President & CEO,
BioCT

Todd Arnold, Ph.D.
Chief Laboratory Operations Officer,
Sema4
BioCT Director

Joni Arvai
Senior Manager, State Government Affairs,
Bristol-Myers Squibb

Kathy Andrews Bilotas
Director of State Government Affairs,
Eli Lilly

Bill Claffey, J.D.
Partner, Tax Services,
Fiondella, Milone & LaSaracina

Jennifer Herz
State Government Affairs, Regional Director,
Boeringer Ingelheim

Ken Hiscoe
Director, US Government Relations/Corporate Affairs,
Pfizer

Richard Jacob
Associate Vice President for Federal Relations,
Yale University
BioCT
 Director

Kathryn Lavriha
Director, State Government Relations,
Sanofi

Joann Lombardo
Senior Director, Government Relations,
University of Connecticut

Delman Lebel
Director, State Government Affairs and Public Policy,
Regeneron Pharmaceuticals

Katherine Lutz
Partner,
Rome, Smith & Lutz

Joseph Oros
Regional Director, State Government Affairs,
AbbVie

Jack Quinn
Head of State Government Affairs,
Alexion

Lonnie Reed
Former State Representative

Dmitri Siegel
Director, Alliance Development
Bristol-Myers Squibb

Christopher Smith
Vice President,
Rome Smith & Lutz

Karla White
State Government Affairs Manager, East Coast,
CSL Behring

Testimony and Issues of Interest  (recent posts)

Senate Bill 1099- AN ACT AUTHORIZING BONDS OF THE STATE FOR A RESEARCH FACULTY RECRUITMENT AND HIRING PROGRAM BY THE UNIVERSITY OF CONNECTICUT TO ENCOURAGE THE CREATION OF NEW BUSINESS VENTURES-SUPPORT

April 20,2021

On behalf of BIO, BioCT and our Board of Directors, as shown, we are writing in support of SB 1099, An Act Authorizing Bonds of the State for a Research Faculty Recruitment and Hiring Program by the University of Connecticut To Encourage the Creation of New Business Venture.

View

Senate Bill 1094- AN ACT AUTHORIZING BONDS OF THE STATE FOR CTNEXT AND THE INNOVATION PLACE PROGRAM

April 20, 2021

On behalf of BIO, BioCT and our Board of Directors, as shown, we are writing in support of SB 1094, An Act Authorizing Bonds of the State for CTNext and the Innovation Place Program.

View

Statement on Governor Lamont’s Budget Proposal to Impose Price Controls on Pharmaceutical Innovations

February 10, 2021

Imposing arbitrary mandates on biopharmaceutical innovation can dry up investment into early stage companies who are innovators in the development of health solutions, and potentially risk lives.

View

Letter to Governor Lamont Regarding Essential Worker Status for Connecticut’s Biotechnology Personnel

January 5, 2021

Those workers involved in research, development and manufacturing of biopharmaceuticals and agricultural biotechnology products should be included in Phase 1B of the CDC’s Advisory Committee on Immunization Practices (ACIP) framework.

View

 

Previous: Testimony and Issues of Interest

Advocacy At the State Level

BioCT’s advocacy wins at the state level include:

  • A $100 million-10-year stem cell research program, the first of its kind
  • 6% tax credit for continuing research and development
  • 20% tax credit for new research and development
  • 65-cents-on-the-dollar refundable R&D tax credit
  • Biopharma sales and use tax exemption
  • 20 year net operating loss carry-forward period
  • Bioscience Innovation Act, a $200 million fund for start-ups and entrepreneurs
  • $1.5 billion Next Generation Connecticut legislation for strengthening STEM education
i am bioct

“BioCT advocates as the voice of the bioscience community. Our goal is to make sure that the legislators understand: who we are, what we do, what we need to be successful, and how critical our industry is to the development of the next therapy and innovation in patient care.”

Dawn Hocevar
President & CEO
BioCT